Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia Patients With Complete Cytogenetic Response Treated With Imatinib as First Line Therapy: Health-Related Quality of Life, Symptom Burden and Adherence to Therapy Issues.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00896129

Enrollment

448

Registered

2009-05-11

Start date

2010-03-31

Completion date

2010-12-31

Last updated

2014-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia

Keywords

Health Outcomes Research, CML

Brief summary

Rationale: At present, virtually no evidence exists regarding mid to long-term patient-reported health outcomes (e.g., health related quality of life-HRQOL) of CML patients treated with Imatinib. Purpose: the results of this research will provide preliminary evidence-based data on an number of issues from the patients' perspective, including adherence to therapy issues.

Detailed description

OBJECTIVES: Primary: to investigate a number of mid to long-term HRQOL issues in Chronic Myeloid Leukemia (CML) patients with complete cytogenetic response treated with Imatinib as First Line Therapy. Secondary evaluation of: * Psychological wellbeing. * Fatigue. * Adherence to therapy issues. * Symptom burden. * Possible association between social-demographic and clinical variables with patient reported health outcomes. OUTLINE:This is a multicenter study. SAMPLE SIZE: Sample size estimation has not been performed considering the nature of the study and the lack of preliminary data to hypothesize the number of possible eligible patients in each center. DURATION OF THE STUDY: The recruitment period is estimated in approximately 6 to 12 months.

Interventions

OTHERHRQOL Survey Packet

Questionnaires

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age 18 years. * CML patients meeting the following criteria: * Started IM therapy in the early chronic phase (ECP). * Have been undergoing treatment with IM, as first line therapy, for at least three years regardless of the current prescribed dose of IM. * In complete cytogenetic response (CCgR) and no clinical evidence of disease progression to accelerated phase (AP) or blast crisis (BC). * Able to read and write Italian. * Freedom from psychiatric conditions that may confound HRQOL evaluation. * Informed consent provided.

Exclusion criteria

* CML patients who were initially diagnosed in the AP or BC or those who started therapy with IM in the late chronic phase (LCP). * Having received any kind of treatment prior to IM therapy (except for hydroxyurea and/or anagrelide). * Patients with a new primary malignancy.

Design outcomes

Primary

Measure	Time frame
Number of mid to long-term HRQOL issues in Chronic Myeloid Leukemia (CML) patients with complete cytogenetic response treated with Imatinib as First Line Therapy.	By the end of the study.

Secondary

Measure	Time frame
Psychological wellbeing.	By the end of the study.
Fatigue.	By the end of the study.
Adherence to therapy issues.	By the end of the study.
Symptom burden.	By the end of the study.
Possible association between socio-demographic and clinical variables with patient reported health outcomes.	By the end of the study.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026